MAPT and Alzheimer disease: This interaction regulates the aging biomarkers P21, P35/25, and P16 and the pro-inflammatory factors TNF-α and NF-κB, and leads to downregulation of tau, P-tau, Aβ-1, and APOE, thereby delaying the onset of AD (154, 155) (Figure 5).